Signals, Powered By EquityPandit
Suven Life Sciences has been granted 3 product patents. The patents are from Norway, South Korea and Singapore respectively corresponding to the New Chemical Entities (NCEs).
They patents are for treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2027, 2034 and 2036 respectively.
The granted claims of the patents include the class of selective 5-HT6 and 5HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment related to neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Venkat Jasti, CEO Suven stated, “We are very pleased by the grant of these patents to the company for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
